Saturday 17 October 2026
Export AMRN’s income statement to Excel — free account
Amarin Corporation PLC
AMRN Healthcare Drug Manufacturers General
Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024. In the quarter to June 2026, revenue fell 42.0%, EPS grew 45.8% and free cash flow fell 60.2%, each against the same quarter a year earlier.
11.37
0.20
−1.73%
Follow AMRN
Amarin Corporation PLC (AMRN) P/E ratio
Amarin Corporation PLC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 993× (August 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 130× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 993×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MDCX Medicus Pharma Ltd compare | n/m |
| SCLX Scilex Holding Company compare | n/m |
| AMRN Amarin Corporation PLC | n/m |
| MIRA MIRA Pharmaceuticals, Inc. compare | n/m |
| GRFS Grifols, S.A. compare | 8.5× |
| OGN Organon & Co. compare | 17.4× |
| SNY Sanofi compare | 21.3× |
| BIIB Biogen Inc. compare | 41.0× |
| NSRX Nasus Pharma Ltd. compare | — |
| Drug Manufacturers General industry median | 24.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)